<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657487</url>
  </required_header>
  <id_info>
    <org_study_id>099013-F</org_study_id>
    <nct_id>NCT01657487</nct_id>
  </id_info>
  <brief_title>Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Ethics Review Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate and compare treatment efficacy with high and medium dose of
      fluticasone in combination with salmeterol in COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis and criteria for inclusion and exclusion:

      Inclusion:

        1. Male or female outpatients aged 40 years≧

        2. Current or ex-smoker, with smoking history 10 pack≧- years

        3. COPD (FEV1/FVC &lt; 70%) patients with post-bronchodilator FEV1 70% ≦predicted value,
           without bronchial reversibility (10% increase post ≦bronchodilator)

      Exclusion:

        1. Diagnosis or suspicion of sleep apnea.

        2. Concurrent rhinitis, eczema, and asthma.

        3. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known
           specific pulmonary disease.

        4. A chest X-ray indicating diagnosis other than COPD that might interfere with the study.

        5. Major disease abnormalities are uncontrolled on therapy.

        6. Alcohol or medication abuse.

        7. Patients had lower respiratory tract infections or received systemic steroid in the 4
           weeks prior to the commencement of study.

        8. Unable or unwilling to comply with all protocol

      Test product:

      fluticasone125 mcg/salmetrol 25 mcg ( Seretide 125 Evohaler ) fluticasone250 mcg/salmetrol 25
      mcg ( Seretide 250 Evohaler ) Formulation: fluticasone/salmeterol, 125/25 mcg/puff Dose: 2
      puffs bid
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of lung function parameters, including post bronchodilation forced expiratory volume in first second (FEV1) and forced vital capacity (FVC), before and after treatment.</measure>
    <time_frame>Lung function change in one year</time_frame>
    <description>We will compare the lung function changed in COPD patients treating with different doses of Fluticasone (500 and 1000ug)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual rate of acute exacerbations</measure>
    <time_frame>percentage of acute exacerbation in one year</time_frame>
    <description>Annual rate of acute exacerbations
The number of use of rescue medication
Annual incidence of community-acquired pneumonia
The changes of Health-related quality of life assessed by questionnaire (CAT or SGRQ) before and after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Percentage of Annual Acute Exacerbation</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Fluticasone/salmeterol high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone/Salmeterol medium dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone/Salmeterol high dose</intervention_name>
    <arm_group_label>Fluticasone/salmeterol high dose</arm_group_label>
    <arm_group_label>Fluticasone/Salmeterol medium dose</arm_group_label>
    <other_name>COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female outpatients aged 40 years≧

          2. Current or ex-smoker, with smoking history 10 pack≧- years

          3. COPD (FEV1/FVC &lt; 70%) patients with post-bronchodilator FEV1 70% ≦predicted value,
             without bronchial reversibility (10% increase post ≦bronchodilator)

        Exclusion Criteria:

          1. Diagnosis or suspicion of sleep apnea.

          2. Concurrent rhinitis, eczema, and asthma.

          3. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known
             specific pulmonary disease.

          4. A chest X-ray indicating diagnosis other than COPD that might interfere with the
             study.

          5. Major disease abnormalities are uncontrolled on therapy.

          6. Alcohol or medication abuse.

          7. Patients had lower respiratory tract infections or received systemic steroid in the 4
             weeks prior to the commencement of study.

          8. Unable or unwilling to comply with all protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Lung Cheng, MD, PhD</last_name>
      <phone>888-2-89667000</phone>
      <phone_ext>2816</phone_ext>
      <email>ntuhwyh61@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Shih-Lung Cheng, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Shih-Lung Cheng</investigator_full_name>
    <investigator_title>Division of Pulmonary Medicine, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Fluticasone/Salmeterol</keyword>
  <keyword>high dose</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

